How do you approach treatment in premenopausal patients who develop a contralateral HR+ breast cancer while already on tamoxifen and ovarian function suppression?
How would you manage endocrine therapy 7 years after the original ER+/PR+/HER2- IDC, while on adjuvant tamoxifen/OFS develops a contralateral ER+/PR+/HER2- cT1c multifocal ILC?
Answer from: Medical Oncologist at Academic Institution
Several pieces of information are lacking in this clinical case to make a solid treatment recommendation: what is the current age of the patient? What is her menopausal status? Is the new contralateral breast cancer clinically node negative?
Since this new second primary contralateral breast cancer...
Sign in or Register to read more
Answer from: Medical Oncologist at Academic Institution
If she doesn't need adjuvant chemo after surgery, I would switch her to OFS+AI for at least 5 years.
Comments
Medical Oncologist at University of Pittsburgh
How about if the patient had already received AI+O...
How about if the patient had already received AI+O...
Medical Oncologist at H Lee Moffitt Cancer Center, University of South Florida
From what I understand, this is a contralateral ne...
From what I understand, this is a contralateral ne...